Long term survival of patients with stage IV gastric carcinoma

Kakeji, Yoshihiro; Maehara, Yoshihiko; Tomoda, Masashi; Kabashima, Akira; Ohmori, Mariko; Oda, Shinya; Ohno, Shinji; Sugimachi, Keizō

doi:10.1002/(sici)1097-0142(19980615)82:12<2307::aid-cncr2>3.0.co;2-p

Cited by 32 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is concordant with a previous French retrospective and single-center study of 180 patients [5], and is also in line with an Asian study that used multivariate analysis and found that the SRC type was associated with a poorer prognosis, albeit not statistically significantly so [35]. In contrast, among the five multivariate studies available [39][40][41][42][43][44] on the prognostic impact of SRC type in gastric adenocarcinoma, the single Western study did not find any impact of SRC type on survival [23], but Taghavi et al acknowledged that although radicality of surgery (R0 or R1-R2) and extent of lymphadenectomy were found to be prognostic factors for overall survival in the literature (and in our multivariate analysis) [39][40][41][42][43][44], these factors were neither controlled nor recorded in their retrospective analysis of the large SEER database [23]. Among the prognostic factors for poor survival found in our study, three are characteristics of patients: patient older than 60 years (HR = 1.33; p = 0.001), high ASA score (HR = 1.265; p \ 0.001), and preoperative malnutrition (HR = 1.432; p \ 0.001).…”

Section: Discussionsupporting

confidence: 91%

Is signet-ring cell carcinoma a specific entity among gastric cancers?

et al. 2015

View full text Add to dashboard Cite

Background The prognosis and chemoresistance of signet-ring cell (SRC) gastric adenocarcinoma have been reported and debated, and the utility of perioperative chemotherapy for such a tumor has been questioned. This study was performed to assess the impact of the SRC type on survival following resection of gastric adenocarcinoma, and to assess whether the prognostic factors (including perioperative chemotherapy) for non-SRC adenocarcinoma differed from those for SRC adenocarcinoma. Methods 1799 cases of adenocarcinoma that were consecutively treated from 1997 to 2010 in 19 French centers by subtotal or total gastrectomy were included in a retrospective study. A D2 lymphadenectomy was performed for antropyloric tumors, and a modified D2 for upper tumors. SRC adenocarcinoma was diagnosed based on the presence of isolated carcinoma cells containing mucin. Results A total gastrectomy was performed in 979 (54.4 %) patients. SRC adenocarcinoma was diagnosed in 899 (50 %) patients. Patients with an SRC tumor were more frequently female, younger, and malnourished, had lower ASA scores, and had larger tumors than non-SRC patients. Median survival in patients with non-SRC carcinoma was 51 months, as compared to 26 months in patients with SRC carcinoma (p \ 0.001). At multivariate analysis, SRC type remained an independent adverse prognostic factor (HR = 1.182). Factors that were prognostic in the SRC subgroup but not in the non-SRC subgroup were age [60 years, linitis, and involvement of adjacent organs. In contrast to non-SRC tumors, pre-and postoperative chemotherapy did not significantly impact on survival following resection of SRC adenocarcinoma. On behalf of the FREGAT (French Eso-GAstric Tumours) working group-FRENCH (Fédération de Recherche en Chirurgie).Electronic supplementary material The online version of this article (doi:10.1007/s10120-015-0564-2) contains supplementary material, which is available to authorized users. Conclusion In comparison to non-SRC adenocarcinoma, the SRC type has a worse prognosis, different prognostic factors, and is only poorly sensitive to perioperative chemotherapy. Non-SRC and SRC adenocarcinomas should be considered different entities in future therapeutic trials.

show abstract

Section: Discussionsupporting

confidence: 91%

Is signet-ring cell carcinoma a specific entity among gastric cancers?

et al. 2015

View full text Add to dashboard Cite

show abstract

“…AgNOR counts per cell correlate well with cell proliferation in several cancers in rodent models 24,26) and in humans. 21,27) Especially, in prostate cancer, AgNOR has been employed as an indicator of histological grade and prognosis. In our previous study, genistein was shown to inhibit the growth of human prostatic cancer cells (LNCaP) due to suppression of DNA synthesis and induction of apoptosis.…”

Section: Discussionmentioning

confidence: 99%

Effects of a Soybean Isoflavone Mixture on Carcinogenesis in Prostate and Seminal Vesicles of F344 Rats

Onozawa

Kawamori

Baba

et al. 1999

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

“…

Moreover, S-1 in combination with other anticancer drugs such as cisplatin (CDDP), taxanes, and irinotecan (CPT-11) increased ORRs and prolonged MST [8][9][10][11].

Paclitaxel is a cytotoxic antineoplastic agent that causes excessive polymerization of tubulin and microtubule dysfunction, resulting in tumor cell death [12].

…”

mentioning

confidence: 99%

“…dissemination still have a poor prognosis [1]; most of these patients die within 6 months of diagnosis, while the 5-year survival rate is nil [2,3].…”

mentioning

confidence: 99%

Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer

et al. 2010

View full text Add to dashboard Cite

dissemination still have a poor prognosis [1]; most of these patients die within 6 months of diagnosis, while the 5-year survival rate is nil [2,3].The recent introduction of an oral drug, S-1, has increased the overall response rates (ORRs) to 44% and 49% and median survival time (MST) to 8 months in phase II studies [4,5].Several reports have demonstrated that S-1 was effective for undifferentiated histological types, such as poorly differentiated adenocarcinoma and signet-ring cell carcinoma, which are relevant to peritoneal dissemination [6]. S-1 has been reported to be effective in prolonging the survival of gastric cancer patients with peritoneal dissemination [4][5][6][7].Moreover, S-1 in combination with other anticancer drugs such as cisplatin (CDDP), taxanes, and irinotecan (CPT-11) increased ORRs and prolonged MST [8][9][10][11].Paclitaxel is a cytotoxic antineoplastic agent that causes excessive polymerization of tubulin and microtubule dysfunction, resulting in tumor cell death [12]. Kobayashi et al. [13] have demonstrated that paclitaxel is a promising drug for the treatment of malignant ascites in patients with gastric cancer: the concentration of paclitaxel in ascites was maintained within the optimal level for the treatment of cancer cells for up to 72 h after intravenous administration.Recent phase II studies of systemic chemotherapy with S-1 plus taxanes have demonstrated strong anticancer effects and a good MST in the treatment of advanced gastric cancer [9,10,14]. However, the effi cacy of systemic chemotherapy for peritoneal dissemination from gastric cancer has been unclear, because peritoneal metastases have not been defi ned as measurable lesions in conventional phase II studies. Therefore, few reports describing the effi cacy of chemotherapy for these lesions are available.In this pilot study, we planned therapeutic strategies to observe the effect of chemotherapy on peritoneal metastasis by second-look laparoscopy for patients Abstract Background. This pilot study was carried out to evaluate the effi cacy of chemotherapy for patients with peritoneal dissemination from gastric cancer or positive lavage cytology diagnosed by staging laparoscopy. Methods. Sixteen patients were enrolled. Paclitaxel was administered at 120 mg/m 2 on day 1 and S-1 was administered orally at 80 mg/m 2 for 14 consecutive days, followed by a 1-week rest, as one course. After fi ve courses of this therapy, the primary gastric tumors were evaluated and second-look laparoscopy was performed for patients showing partial response or stable disease with clinical benefi t. Results. Partial response or stable disease with clinical benefi t was confi rmed in seven and fi ve patients, respectively, and these patients underwent second-look laparoscopy. No viable cancer cells were detected on cytopathological investigation during second-look laparoscopy in 9 patients who underwent surgical treatment. The intent-to-treat response rate for gastric tumor was 44% and the rate of disappearance of peritoneal metastasis was 38% ...

show abstract

Long term survival of patients with stage IV gastric carcinoma

Cited by 32 publications

References 17 publications

Is signet-ring cell carcinoma a specific entity among gastric cancers?

Is signet-ring cell carcinoma a specific entity among gastric cancers?

Effects of a Soybean Isoflavone Mixture on Carcinogenesis in Prostate and Seminal Vesicles of F344 Rats

Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer

Contact Info

Product

Resources

About